CClinicalTrials.gg
CompletedNCT06371092Updated Apr 17, 2024

Efficacy of a Desensitizing Agent During At-home Bleaching

An Early Phase 1 interventional study of UltraEZ and Placebo in Sensitivity, Tooth, sponsored by University of Santiago de Compostela. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by University of Santiago de Compostela · Early Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 7 months ago, and no results have been posted to the registry.
  • Registered 1 year 2 months after the study started (first participant enrolled Jan 2023, registered Apr 2024).
Phase
Early Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this study is to evaluate if the use of UltraEZ during at-home bleaching treatment is effective in reducing tooth sensitivity, as well as doesn't affect the degree of tooth bleaching.

Read the detailed description
  1. Visit 1: Study information and delivery of informed consent. Recording of the patient's medical history, general examination, and prophylaxis. Alginate impressions will be taken of the upper and lower arches for all patients who meet the inclusion criteria. The impressions will be poured into plaster, and individualized bleaching trays will be made for each patient. A positioning guide tray will be fabricated for color measurement.
  2. Visit 2: Initial color measurement with a spectrophotometer and the positioning guide. Each patient will receive their individualized trays. Additionally, they will be given 3 syringes of bleaching agent (Opalescence 16%, Ultradent Products) and one syringe of desensitizing agent (UltraEZ, Ultradent Products) or placebo (glycerin), according to their study group. Both the desensitizing agent and placebo will be dispensed in identical syringes, coded as A and B, to ensure the blinding of the study; only the clinician responsible for randomization knows the coding. Each patient will be provided with an instruction sheet and recording sheets to fill out daily during the 3-week study period. They will record the degree of dental sensitivity .
  3. Visit 3: First-week bleaching review. Data collection (color + sensitivity).
  4. Visit 4: Second-week bleaching review. Data collection (color + sensitivity).
  5. Visit 5: Third-week bleaching review and end of the study. Data collection (color + sensitivity).
02

Conditions studied

  • Sensitivity, Tooth

Keywords

  • Tooth bleaching
  • Vital bleaching
  • Desensitizing agents
  • Tooth sensitivity
03

In context

Dentin Sensitivity

283 studies on the registry are indexed under Dentin Sensitivity; 45 are open to participants now.

This study's enrollment of 32 is below the median of 60 across 274 interventional studies indexed under Dentin Sensitivity.

Browse Dentin Sensitivity studies →

Lead sponsor

University of Santiago de Compostela is the lead sponsor of 59 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • No oral or systemic pathology
  • Periodontally healthy
  • No cavities
  • Tooth shade of the upper and lower canines A2 or darker

Exclusion criteria

Exclusion Criteria:

  • Adhesive restorations or prostheses in the anterior region
  • Enamel or dentin alterations
  • Smoking
  • Pregnant women
  • Undergone prior bleaching treatment
05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    UltraEZ Group

    Patients put in their bleaching trays the UltraEZ desensitizing gel for 30 minutes before the bleaching treatment every day during three weeks.

    Drug: UltraEZ

  • Placebo comparator
    Placebo Group

    Patients put in their bleaching trays the UltraEZ placebo gel for 30 minutes before the bleaching treatment every day during three weeks.

    Drug: Placebo

Interventions

  • DrugUltraEZ

    General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the UltraEZ gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours

  • DrugPlacebo

    General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the placebo gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours

06

What researchers measure

Primary outcomes

  1. Questionnaire of dental sensitivity

    Patients should answer a dental sensitivity questionnaire. A a 5-point subjective numerical classification scale will be used (0=no sensitivity, 1=light, 2=mild, 3=considerable and 4=severe). Patients will a score of 0 during the treatment will be defined as patients with no sensitivity. The individual highest recorded score will be the grade of intensity for each patient.

    Time frame: Daily, during 3 weeks

Secondary outcomes

  1. Shade evaluation with a dental spectrophotometer

    The color will be measured with a dental spectrophotometer and the parameters L (Lightness), C (Chroma) and H (Hue) will be recorded. To determine the color change between visits the CIEDE2000 formula will be used.

    Time frame: Once a week, during 3 weeks

07

Study locations

1 site
  • School of Medicine and Dentistry
    Santiago De Compostela, A Coruña 15705, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06371092
Lead sponsor
University of Santiago de Compostela
Responsible party
Patricia Pereira-Lores (Principal Investigator, University of Santiago de Compostela) — Principal investigator
First posted
Apr 17, 2024
Start date
Jan 31, 2023
Primary completion
Feb 22, 2023
Completion
Mar 1, 2023
Last update
Apr 17, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion